Navigation Links
Cynvenio Announces New Deployment of LiquidBiopsy® System at Leading Cancer Research Center in South Korea
Date:7/27/2017

Cynvenio Biosystems, Inc. a leader in liquid biopsy technology for cancer research and precision medicine, today announced that its LiquidBiopsy rare cell and cell-free isolation platform has been deployed at Severance Hospital of the Yonsei University Health System. Located in Gangnam-Gu, Seoul, Severance Hospital is one of the oldest and largest university hospitals in South Korea and has been treating patients continuously for 130 years.

The LiquidBiopsy system at Severance Hospital will enable quick-turnaround blood sample-to-sequence workflows supporting genomic research and testing for cancer patients. The system will support programs across various indications including breast, prostate and lung cancer.

"The LiquidBiopsy system will significantly improve our sequencing workflows, allowing our lab to operate at a higher scale,” said Joon Jeong, M.D., Ph.D., Professor of the Department of Surgery and Director of the Breast Cancer Center at Gangnam Severance Hospital. “This new application will allow us to deliver high-quality clinical test results faster from whole blood samples, taking our cancer patient care to the next level by personalizing their treatment.”

The LiquidBiopsy platform is a turn-key system that supports a number of key liquid biopsy applications, including the isolation of circulating tumor cells (CTCs) to gain access to their DNA and RNA, cell-free DNA (cfDNA), exosomes, and platelets. The platform delivers ultra-high purity output that enables downstream molecular characterization such as protein analysis of CTCs and sequencing of the isolated DNA/RNA. This allows researchers gain a better understanding of tumor heterogeneity and provides access to clinically actionable biomarkers from a standard blood sample.

“We are extremely happy to support Prof. Jeong’s work at Gangnam Severance Hospital and look forward to his continued success in cancer research and novel patient treatment,” commented André de Fusco, Cynvenio’s CEO, “To advance medical knowledge and improve patient outcomes we are making our LiquidBiopsy technology available cost-effectively to hospitals and research centers worldwide.”

About Cynvenio Biosystems, Inc.

Cynvenio’s LiquidBiopsy testing technology is leading the way to more affordable and clinically actionable precision medicine strategies for cancer patients.  Among the company’s breakthroughs is its line of ClearID® tests for greatly improved cancer detection and monitoring via a patient-friendly blood draw, and a suite of proprietary, distributable LiquidBiopsy® platforms and consumables for deployment in hospitals and third party diagnostic labs. Cynvenio is based in Westlake Village, California. For more information, please visit http://www.cynvenio.comhttp://www.clearidmonitoring.com, and http://www.liquidbiopsy.com.

LiquidBiopsy is CE-marked and registered with the CFDA in China.
LiquidBiopsy® and ClearID® are registered trademarks of Cynvenio Biosystems, Inc.

Read the full story at http://www.prweb.com/releases/2017/07/prweb14549288.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Cynvenio Biosystems to Present Clinical Data on Mutational Analysis of LiquidBiopsy® Tumor Samples at the 2013 ASCO Annual Meeting
2. Cynvenio Biosystems Receives CLIA Certification for its Genomic Sequencing Laboratory
3. Cynvenio and CollabRx Announce Partnership for Cancer Molecular Diagnostics
4. Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test
5. Cynvenio Biosystems Announces Expansion of Payer Network with Addition of Blue Cross Blue Shield of Illinois
6. Cynvenio Releases Two New High Recovery LiquidBiopsy® CTC Capture Kits at 2017 AACR Annual Meeting in Washington, DC.
7. Cynvenio and TME Research Announce Neoadjuvant Breast Cancer Monitoring Study (NEAT)
8. Cynvenio Releases ClearID® Lung Cancer: a Highly-Targeted Genomic Blood Test for Lung and Thoracic Cancer Patients
9. Cynvenio Research Highlights Need for Longitudinal Monitoring of Triple Negative Breast Cancer Patients
10. Cynvenio’s LiquidBiopsy® Platform-Derived Research Data to be Presented at the 2017 ASCO Annual Meeting, June 2-June 6, 2017 in Chicago, Illinois
11. Cynvenio Announces ClearID® Commercial Distribution Agreements for Israel, Greece, Argentina and South Korea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... At its national ... Dr. Suneel I. Sheikh, the co-founder, CEO and chief research scientist of Minnesota-based ... selected for membership in ARCS Alumni Hall of Fame . ASTER Labs ...
(Date:10/11/2017)... a leading provider of patient support solutions, has announced the ... which will launch this week. The VMS CNEs will address ... enhance the patient care experience by delivering peer-to-peer education programs ... to help women who have been diagnosed and are being ... ...
(Date:10/10/2017)... ... , ... San Diego-based team building and cooking events company, Lajollacooks4u, has unveiled ... bold new look is part of a transformation to increase awareness, appeal to new ... , It will also expand its service offering from its signature gourmet cooking classes ...
(Date:10/10/2017)... Calif. , Oct. 10, 2017 SomaGenics ... from the NIH to develop RealSeq®-SC (Single Cell), expected ... for profiling small RNAs (including microRNAs) from single cells ... Program highlights the need to accelerate development of approaches ... "New techniques for measuring levels ...
Breaking Biology Technology:
(Date:4/5/2017)... April 5, 2017 Today HYPR Corp. ... the server component of the HYPR platform is officially ... the end-to-end security architecture that empowers biometric authentication across ... has already secured over 15 million users across the ... of connected home product suites and physical access represent ...
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
(Date:3/30/2017)... 2017  On April 6-7, 2017, Sequencing.com will host ... hackathon at Microsoft,s headquarters in Redmond, ... on developing health and wellness apps that provide a ... Genome is the first hackathon for personal genomics ... companies in the genomics, tech and health industries are ...
Breaking Biology News(10 mins):